|
|
|
|
|
|
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Preliminary Efficacy, Immunogenicity and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor that is being developed to address the fibro-inflammatory pathology of pulmonary fibrosis and TED. This study is a four-part trial consisting of Parts A, B, C and D.
The primary objective of this study is to evaluate the safety and tolerability of LASN01, and the secondary objective is to evaluate the preliminary efficacy, immunogenicity, and pharmacokinetics of single and multiple doses of LASN01 in healthy participants and in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrosing interstitial lung disease (PF-ILD) or Thyroid Eye disease (TED).
Please note that the Phase 1 (single and multiple ascending dose, SAD/MAD) portion in healthy subjects is completed and the Phase 2a portion in patients is no longer recruiting.
100 项与 Lassen Therapeutics 1 Pty Ltd. 相关的临床结果
0 项与 Lassen Therapeutics 1 Pty Ltd. 相关的专利(医药)
100 项与 Lassen Therapeutics 1 Pty Ltd. 相关的药物交易
100 项与 Lassen Therapeutics 1 Pty Ltd. 相关的转化医学